1-15 of 15
Monica Mead
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Michael J. Maranzano, Justin Cheng, John Timmerman, Patricia A. Young, Caspian H. Oliai, Herbert A. Eradat, Sven de Vos, Sarah M. Larson, Monica Mead
Journal: Blood
Blood (2023) 142 (Supplement 1): 7358.
https://doi.org/10.1182/blood-2023-182105
Published: 2023
Journal Articles

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Benjamin R Puliafito, Christopher M Walthers, Brenda Ji, Sanaz N Ghafouri, Jacob Naparstek, Jacqueline Trent, Jia Ming Chen, Mobina Roshandell, Caitlin Harris, Mobina Khericha, Melanie Ayala Ceja, Christy Sidhu, Thomas Schweppe, Beata Berent-Maoz, Stanley B Gosliner, Amr Almaktari, Karla Nawaly, Martin S Allen-Auerbach, Jonathan Said, Monica Mead, Sven de Vos, Patricia A. Young, Caspian H. Oliai, Gary J. Schiller, John Timmerman, Antoni Ribas, Yvonne Y Chen, Sarah M. Larson
Journal: Blood
Blood (2023) 142 (Supplement 1): 3490.
https://doi.org/10.1182/blood-2023-186636
Published: 2023
Journal Articles

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Pier Luigi Zinzani, Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael D. Jain, Timothy Voorhees, Adam S Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera, Agrima Mian, Brian T. Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Lisa Argnani
Journal: Blood
Blood (2023) 142 (Supplement 1): 6938.
https://doi.org/10.1182/blood-2023-178526
Published: 2023
Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Marci Daugherty, Jonathan E Brammer, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 9387–9389.
https://doi.org/10.1182/blood-2022-169432
Published: 2022
Journal Articles

A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE) (NCT05181540) - Trials in Progress

Michael Scordo, Geoffrey Shouse, Luke Mountjoy, Jordan Gauthier, Bhagirathbhai Dholaria, Scott D. Rowley, Jeremy M. Pantin, Zachariah Defilipp, Monica Mead, Paul Finnegan
Journal: Blood
Blood (2022) 140 (Supplement 1): 10573–10574.
https://doi.org/10.1182/blood-2022-162373
Published: 2022
Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Secondary Central Nervous System Lymphoma

Daria Gaut, Caspian Oliai, Monica Mead
Journal: Blood
Blood (2021) 138 (Supplement 1): 4911.
https://doi.org/10.1182/blood-2021-145358
Published: 2021
Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

Jonathan E Brammer, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Eric D Jacobsen, Giuseppe Gritti, Debra Litwak, David Cohan, Danica J Katz, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz
Journal: Blood
Blood (2021) 138 (Supplement 1): 2456.
https://doi.org/10.1182/blood-2021-148939
Published: 2021
Journal Articles

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Erel Joffe, MD MSc, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Monica Mead, MD BS, Daniel J. Landsburg, MD, Timothy S. Fenske, MD, Radhakrishnan Ramchandren, Praveen Ramakrishnan Geethakumari, MD MS, Alan Skarbnik, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD, Han W. Tun, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-140884
Published: 2020
Journal Articles

Impact of Comorbidities on Outcomes of Peripheral T Cell Lymphoma in Elderly Patients: An International Retrospective Study

Monica Mead, MD BS, Henrik Cederleuf, MD, Thomas Relander, MD PhD, Mats Jerkeman, MD PhD, Fredrik Ellin, MD PhD, Daria Gaut, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-134814
Published: 2020
Journal Articles

Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations

Mao Yu Peng, PhD, Yasmin Abaza, MD, Martina Mcdermott, PhD, Monica Mead, MD BS, Dennis J. Slamon, MD PhD, Sarah Larson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-141459
Published: 2020
Journal Articles

Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia

Sanaz Ghafouri, MD, Christopher Walthers, PhD, Mobina Roshandell, MS, Brenda Ji, BS, Jacqueline Trent, Jia Ming Chen, PhD, Jacob Naparstek, Monica Mead, MD BS, John M. Timmerman, MD, Yvonne Chen, Sarah Larson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-137630
Published: 2020
Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

Barbara Pro, MD, Jonathan E. Brammer, MD, Carla Casulo, MD, Eric Jacobsen, MD, Monica Mead, MD BS, Neha Mehta-Shah, MD, Jasmine M. Zain, MD, Pier Luigi Zinzani, MD, Stephanie Lustgarten, PhD, Hagop Youssoufian, MD, Steven M. Horwitz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-140412
Published: 2020
Journal Articles

Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma

Sarah M Larson, MD, Mao Yu Peng, PhD, Monica Mead, MD BS, Andrae Vandross, MD, Dylan Conklin, PhD, Erika Von Euw, PhD, Dennis J. Slamon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3084.
https://doi.org/10.1182/blood.V130.Suppl_1.3084.3084
Published: 2017
Journal Articles

Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma

Sarah M Larson, MD, Mao Yu Peng, PhD, Andrae Vandross, MD, Monica Mead, MD BS, Zoe Fuchs, Dylan Conklin, PhD, Erika Von Euw, PhD BS, Dennis J. Slamon, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5665.
https://doi.org/10.1182/blood.V128.22.5665.5665
Published: 2016
Journal Articles

Efficacy and Mechanism of Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies

Monica Mead, MD BS, Erika Von Euw, PhD BS, Dylan Conklin, Ben Powell, PhD BS, Kanthinh Manivong, BS, Eileen Do, Dennis J. Slamon, MDPhD, Sarah Larson, MD
Journal: Blood
Blood (2015) 126 (23): 3702.
https://doi.org/10.1182/blood.V126.23.3702.3702
Published: 2015